Our vision is to work towards truly personalised medicine, where every patient receives individualised treatment to improve their health outcomes. By embracing the most advanced technology and utilising our invaluable partnerships, Roche harnesses the power of our unique network to advance and develop new therapies and diagnostic tests.
Accelerating and improving individualised treatment options for cancer and critical care patients through the development of digital clinical decision-making solutions is at the core of our strategic, long term partnership with GE Healthcare.
Roche subsidiary, Flatiron Health, is driving personalised healthcare and pioneering the curation and development of real-world evidence in cancer research thanks to our leadership in data analytics.
Roche is investigating innovative smartphone-based self-monitor technology to gain greater insights into multiple sclerosis (MS). Our new global study, FLOODLIGHT Open, will monitoring disease activity and disability progression over the whole 365 days in a year that someone lives with MS, versus just the two or three days a year they may visit their neurologist. FLOODLIGHT will open in Australia in 2019.
Roche is piloting a number of tele-trials in Australia, including one for lung cancer. The tele-trial model uses tele-health to enable clinicians from larger centres (primary sites) to enrol, consent and treat patients on clinical trials at regional and rural centres (satellite sites).
Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278. This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances. To report a suspected side effect or product complaint associated with the use of a Roche product, visit